Full-Time

Associate Clinical Operations Compliance Director

Biotechnology Oncology

Updated on 9/10/2026

Exelixis

Exelixis

1,001-5,000 employees

Biopharmaceutical oncology company developing cancer therapies

Compensation Overview

$168.5k - $238.5k/yr

+ Annual bonus + Long-term incentives

Alameda, CA, USA

In Person

Bachelor's, Master's, PhD

Category
Biology & Biotech (1)
Required Skills
Word/Pages/Docs
Quality Assurance (QA)
Risk Management
Excel/Numbers/Sheets
Microsoft Outlook

Get referred to Exelixis

See people who can refer or advise you

Requirements
  • A bachelor’s degree in a related discipline and a minimum of 11 years of related experience, or a master’s degree in a related discipline and a minimum of 9 years of related experience, or a doctoral degree in a related discipline and a minimum of 5 years of related experience, or an equivalent combination of education and experience.
  • Experience in the biotechnology or pharmaceutical industry.
  • Current understanding of the relevant external scientific, legal, and regulatory environment.
  • Strong knowledge of biopharmaceutical industry regulations, standards, and best practices.
  • Ability to work independently with minimal supervision.
  • Analytical, strategic thinking, problem-solving, time management, change management, and organizational skills, with the ability to work in a fast-paced environment and adapt to changing business plans and priorities.
  • Strong interpersonal, verbal, and written communication skills.
  • Strong attention to detail.
  • Ability to identify and communicate issues and risks.
  • Presentation skills.
  • Ability to build and maintain strong relationships.
  • Ability to influence without direct authority.
  • Advanced knowledge of Microsoft Excel, Word, PowerPoint, and Outlook.
Responsibilities
  • Support the risk and issue management process for Clinical Operations, focusing on compliant delivery of study execution.
  • Contribute to the strategy and methodology for functional risk and issue management, assist in creating the annual functional risk management plan to ensure inspection readiness, collaborate cross-functionally on risk management activities, and escalate issues to appropriate governance.
  • Support Clinical Operations and other functions with embedded compliance roles for CAPA ownership, including owner assignment, follow-up, and completion.
  • Assist with updates on CAPA completion data, including late, near-due, and due-later items.
  • Work closely with and act as a liaison for the Quality Assurance team and other functional teams across Research and Development and beyond.
  • Build a standardized Good Clinical Practice and process-training curriculum, drive ongoing capability and knowledge sharing, and build and renew quality metrics to track progress and consistency across Clinical Operations.
  • Drive continuous inspection readiness across studies, keep the Trial Master File audit-ready, run mock inspections and CAPA follow-up, and lead BIMO and health authority inspection responses.
  • Provide oversight of monitoring quality and contract research organization performance, review risk-based monitoring signals, and ensure timely escalation of site and data issues.
  • Perform other duties as assigned.
  • Comply with all policies and standards.

Exelixis develops and commercializes medicines for cancer. Its products aim to treat advanced cancers, including renal cell carcinoma, by targeting multiple biological pathways and supporting combination regimens to achieve effective, tolerable, and durable responses. The company generates revenue from sales of approved therapies and strategic partnerships, backed by extensive research, clinical trials, and regulatory approvals to bring new drugs to market. Compared with peers, Exelixis focuses on a pipeline that combines multi-pathway targeting with combination therapies to improve patient outcomes. Its overall goal is to advance cancer treatment and offer patients better chances of remission through its ongoing drug development programs.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

San Francisco, California

Founded

1994

Get referred to Exelixis

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenues reached $628.7 million, with CABOMETYX U.S. sales up 10%.
  • Exelixis repurchased $311.6 million in Q2 2026 and extended authorization through 2027.
  • Zanzalintinib’s STELLAR-303 data support a December 2026 FDA decision and launch preparations.

What critics are saying

  • CABOMETYX concentration leaves Exelixis exposed if renal and NET demand slows again.
  • FDA review ends December 3, 2026; a narrow zanzalintinib label crushes launch economics.
  • Teva can launch CABOMETYX generics January 1, 2031, threatening the cash engine.

What makes Exelixis unique

  • CABOMETYX remains a multi-indication oncology franchise with durable U.S. demand in 2026.
  • Exelixis paired disciplined buybacks with pipeline expansion, retiring 93.3 million shares since 2023.
  • Zanzalintinib targets colorectal cancer first, then six additional pivotal programs across tumor types.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Flexible Work Hours

Paid Vacation

Paid Sick Leave

Paid Holidays

401(k) Retirement Plan

401(k) Company Match

Performance Bonus

Employee Stock Purchase Plan

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

3%

2 year growth

2%
Yahoo Finance
Aug 24th, 2026
Exelixis retires 8% of shares with $1.1B buyback as zanzalintinib awaits December FDA decision

Exelixis has spent approximately $1.1 billion buying back its own shares over the past year, reducing shares outstanding by 8.0%. This mechanical effect means existing shareholders now hold larger stakes in the business without taking any action. The company's CABOMETYX oncology drug generated $573 million in US net product revenue in the second quarter of 2026, up roughly 10% year-on-year. Exelixis converts 47.5% of revenue into free cash flow, which funds the buyback programme. The company has revised its 2026 total revenue guidance downward to $2.50 billion to $2.55 billion, lowering the midpoint by $50 million. Management attributed this to a slower ramp for the neuroendocrine tumour indication. The stock trades at 15.8 times trailing earnings. The company's next growth driver, zanzalintinib, awaits a regulatory decision for colorectal cancer in early December 2026.

Investor's Business Daily
Aug 5th, 2026
Why this top-ranked IBD 50 stock just plummeted on its earnings.

Why this top-ranked IBD 50 stock just plummeted on its earnings. * ALLISON GATLIN * Updated 05:08 PM ET 08/05/2026 IBD 50 stock Exelixis (EXEL) toppled late Wednesday on a mixed second-quarter report, as sales of its bread-and-butter cancer drug, cabozantinib, lagged expectations. The biotech company sells cabozantinib under the brand names Cabometyx and Cometriq. The former - a treatment for kidney, liver and thyroid cancers as well as neuroendocrine tumors - brought in $570.6 million in quarterly sales. Cometriq, which treats a form of thyroid cancer, generated $2.4 million in sales. But analysts called for a healthier $578 million and $3 million in sales, respectively. Biotech's Next Boom? Inside The Multibillion Dollar Cancer Detection Market On this episode of Growth Stories, Investors take a look at the groundbreaking tests that could revolutionize cancer detection and what investors need to know about this evolving market. 0 seconds of 10 minutes, 57 secondsVolume 0% Biotech's Next Boom? Inside The Multibillion Dollar Cancer Detection Market See All Videos In response, Exelixis stock slumped more than 5% in after-hours trades on today's stock market, hitting 53.50. Exelixis' sales disappointment. The sales disappointment led Exelixis to cut its earnings outlook for the year. The company now sees $2.5 billion to $2.55 billion in sales. At the midpoint, that's a drop of $50 million from Exelixis' prior guidance from three months ago. More promisingly, Exelixis topped earnings forecasts, reporting an adjusted 91 cents per share, vs. the Street's forecast for 85 cents, according to FactSet. Earnings grew more than 21% as total sales climbed close to 11%, reaching $627.8 million. That includes sales of Cabometyx and Cometriq, as well as $53.2 million in royalties from partners Ipsen and Takeda Pharmaceutical. But sales lagged projections for $636 million. Investors are now watching closely the next steps for zanzalintinib. The Food and Drug Administration is reviewing the experimental prostate cancer treatment for potential approval in December. Exelixis stock is trading above its key moving averages with a nearly perfect IBD Digital Composite Rating of 98. The CR is a 1-99 measure of a stock's fundamental and technical performance. The stock also has a strong Relative Strength Rating of 90, putting its 12-month performance in the leading 10% of all stocks. Exelixis stock ranks No. 16 on the IBD 50 list of elite growth stocks. IBD newsletters. Get exclusive IBD analysis and actionable news daily. Follow Allison Gatlin on X/Twitter at @AGatlin_IBD. YOU MAY ALSO LIKE:

Business Wire
Aug 5th, 2026
Exelixis reports Q2 2026 revenues of $628.7M, up 11% on cabozantinib growth

Exelixis reported second quarter 2026 total revenues of $628.7 million, up from $568.3 million in the same period last year. Net product revenues reached $573.0 million, compared to $520.0 million in 2025, driven primarily by increased sales volume. The company reported GAAP net income of $212.1 million, or $0.82 per diluted share, versus $184.8 million, or $0.65 per diluted share, in the prior year period. Research and development expenses increased to $212.0 million from $200.4 million. Exelixis is preparing for a potential launch of zanzalintinib in metastatic colorectal cancer, pending regulatory approval. The FDA assigned a target action date of 3 December 2026 for the new drug application. The company expects topline results from its phase 3 STELLAR-304 trial in the second half of 2026.

San Francisco Biotechnology Network
May 30th, 2026
Exelixis announces results from subgroup analysis of phase 3 CABINET pivotal trial evaluating CABOMETYX(R)(cabozantinib) in non-functional and functional neuroendocrine tumors at ASCO 2026.

Exelixis announces results from subgroup analysis of phase 3 CABINET pivotal trial evaluating CABOMETYX(R)(cabozantinib) in non-functional and functional neuroendocrine tumors at ASCO 2026. May 30, 2026 san francisco biotechnology network news news, syndication comments off on exelixis announces results from subgroup analysis of phase 3 CABINET pivotal trial evaluating CABOMETYX(R)(cabozantinib) in non-functional and functional neuroendocrine tumors at ASCO 2026. ALAMEDA, Calif.-(BUSINESS WIRE)-Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal trial, which showed that CABOMETYX(R)(cabozantinib) provided significant improvements in progression-free survival (PFS) versus placebo in patients with previously treated advanced neuroendocrine tumors (NET) regardless of functional status. These data will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting to be held fr Click here to view original post

Yahoo Finance
May 22nd, 2026
Exelixis posts $611M Q1 revenue, FDA accepts colorectal cancer drug application

Exelixis, an oncology-focused biopharmaceutical company, reported total revenues of $610.8 million for Q1 2026, up from $555.4 million in Q1 2025. US net product revenues from its cabozantinib franchise reached $555 million, whilst collaboration revenues rose to $55.8 million. The company achieved GAAP net income of $210.5 million and non-GAAP net income of $232.8 million. The US FDA accepted Exelixis's first NDA for zanzalintinib combined with atezolizumab for previously treated metastatic colorectal cancer, with a target action date of 3 December. The company is progressing multiple zanzalintinib clinical trials, including upcoming data readouts for STELLAR-303 and STELLAR-304 studies. Exelixis expects to complete its $750 million share repurchase programme this month. The Board authorised a new $750 million buyback programme through end-2027.